Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Pieda Study: A Phase 3b Investigation Of Erythropoietin Drugs Using A Specified Dosing Algorithm: A Randomized Open Label Dosing Study In Adult Chronic Kidney Disease Subjects On Hemodialysis

NCT02504294 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02504294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02504294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Pieda Study: A Phase 3b Investigation Of Erythropoietin Drugs Using A Specified Dosing Algorithm: A Randomized Open Label Dosing Study In Adult Chronic Kidney Disease Subjects On Hemodialysis
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
July 13, 2015
Completion date
July 16, 2016
Enrollment
432 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease (ckd)